News | September 09, 2025
Congruence gets $32 million financing to advance genetic obesity candidate drug
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Subscribe To Our Newsletter & Stay Updated
